{
    "clinical_study": {
        "@rank": "8083", 
        "brief_summary": {
            "textblock": "This non-interventional, observational study is set up on request of the Belgian\n      reimbursement authorities and evaluates the efficacy of Targinact with regard to pain relief\n      and constipation in daily clinical practice in Belgium compared to the previous analgesic\n      treatment with prolonged release oxycodone. Only patients eligible for Targinact\u00ae\n      reimbursement in Belgium are included."
        }, 
        "brief_title": "A Non-interventional, Observational Study for Targinact\u00ae Treatment in Patients With Chronic Severe Pain", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Severe Pain", 
        "detailed_description": {
            "textblock": "Patients are treated with Targinact\u00ae according to daily clinical practice during at least 12\n      weeks and are monitored during study 3 visits. Parameters assessed are pain relief,\n      constipation, use of laxatives, use of analgesic rescue medication, use of concomitant\n      medication, quality of life and safety of Targinact\u00ae treatment. These parameters, except for\n      safety assessment, are compared between Targinact\u00ae treatment and previous analgesic\n      treatment with prolonged release oxycodone."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria: patients included are patients who\n\n          -  are eligible for Targinact\u00ae treatment according to the Targinact\u00ae SPC AND\n\n          -  who have previously been treated with PR oxycodone during at least the last 30 days\n             before study inclusion AND\n\n          -  who are constipated (BFI > 30) AND\n\n          -  have used at least 2 laxatives with different modes of action during the previous PR\n             oxycodone treatment\n\n        Exclusion criteria are based on Targinact\u00ae SPC."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Primary and Secondary Care"
            }
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710904", 
            "org_study_id": "OXN9511"
        }, 
        "intervention": {
            "intervention_name": "Targinact\u00ae (oxycodone/naloxone)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Naloxone", 
                "Oxycodone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chronic pain", 
            "Severe pain", 
            "Oxycodone", 
            "Naloxone", 
            "Opioid-induced constipation", 
            "Opioid", 
            "Quality of life", 
            "Laxative", 
            "Analgesic rescue medication"
        ], 
        "lastchanged_date": "November 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Brussels", 
                    "country": "Belgium"
                }, 
                "name": "University Hospital Brussels"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Evaluation of Targinact\u00ae in Daily Practice, With Regards to Pain Relief and Constipation, in Chronic Severe Pain Patients Compared to Previous Prolonged Release Oxycodone Treatment: a Non-interventional, Observational Study.", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "A responder is defined as a patient who shows no worsening of pain (pain score has increased \u2264 1 unit on a 11-points pain NRS) at V3/the last visit compared to V1 or has a NRS \u22644 on a 11-points pain NRS at V3/the last visit AND has a reduction in BFI \u2265 12 units at V3/the  last visit compared to V1 or has a BFI \u226430 at V3/ the last visit.", 
            "measure": "Percentage of responders after Targinact treatment compared to the previous treatment with prolonged release oxycodone.", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710904"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess laxative use during Targinact\u00ae treatment compared to previous PR oxycodone treatment (by physician)", 
                "measure": "To assess laxative use during Targinact\u00ae treatment compared to previous PR oxycodone treatment (by physician)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "To assess the use of analgesic rescue medication during Targinact\u00ae treatment compared to previous PR oxycodone treatment (by physician)", 
                "measure": "To assess the use of analgesic rescue medication during Targinact\u00ae treatment compared to previous PR oxycodone treatment (by physician)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "To evaluate the quality of life (EQ-5D questionnaire) during Targinact\u00ae treatment compared to previous PR oxycodone treatment (by patient)", 
                "measure": "To evaluate the quality of life (EQ-5D questionnaire) during Targinact\u00ae treatment compared to previous PR oxycodone treatment (by patient)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Safety will be assessed by documentation of adverse events, collected via spontaneous reports and patient documentation.", 
                "measure": "To assess safety of Targinact\u00ae treatment (by physician)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Mundipharma CVA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mundipharma CVA", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}